LANCE MICHAEL SILVERMAN, MD

Plain English
This study looked at a medication called somapacitan, given once a week, for children with growth hormone deficiency (GHD) over seven years. The results showed that after 364 weeks, children using somapacitan had steady increases in growth measures, with 73% of younger children completing the treatment successfully and experiencing less hassle compared to those on daily growth hormone injections. Importantly, there were no new safety issues identified during this long-term study. Who this helps: This helps children with growth hormone deficiency and their families by offering a more convenient treatment option.

Plain English
Researchers studied a new growth hormone called somapacitan, given once a week, to see if it could help children who are short because they were born small for their age. In their trial with 142 children, those who received somapacitan grew an average of 11.0 cm in a year, which is better than the 9.4 cm and 11.1 cm growth seen with two different daily growth hormone doses. This is important because somapacitan proves to be just as effective and safer than daily injections, making it easier for families to manage treatment. Who this helps: This benefits children born small for their age and their families.

Plain English
This study looked at the role of a protein called ELMO1 in helping the kidneys recover from sudden damage known as acute kidney injury (AKI). Researchers found that mice lacking ELMO1 experienced more kidney damage when given a drug called cisplatin, with increased cell death compared to normal mice. Understanding how ELMO1 contributes to kidney health can lead to new treatments for AKI, which currently has high rates of complications and death. Who this helps: This helps patients at risk for acute kidney injury.

Plain English
This study looked at how certain genetic and molecular features in children with acute lymphoblastic leukemia (ALL) are linked to a serious complication called venous thromboembolism (VTE), which can occur soon after diagnosis. Out of 248 children, 56 (or 23%) developed VTE, and specific gene expressions related to blood clotting and immune response were found to be linked to these events. Identifying these markers can help improve monitoring and treatment for children at risk of developing VTE during their leukemia treatment. Who this helps: This helps young patients with acute lymphoblastic leukemia and their doctors.

Plain English
In this study, researchers examined the brain of a 3-year-old cynomolgus monkey and found two abnormal growths in the left side of the brain. Upon closer inspection, these growths were identified as glioneuronal hamartomas, which are tumors made up of nerve and support cells, but without significant cell growth. This discovery is important because it marks the first documented case of this type of lesion in a nonhuman primate, helping to broaden our understanding of brain tumors. Who this helps: This helps researchers and veterinarians working with primate health.

Plain English
This study looked at how mutations in a specific gene (SRSF2) affect certain blood stem cells in patients with myelodysplastic syndromes (MDS), a type of blood cancer. Researchers found that MDS cells with the SRSF2 mutation are less responsive to signals from a protein called interferon that normally helps control cell growth and inflammation. When they treated these mutated cells with a drug called bortezomib, it increased the levels of a signaling protein (STAT1) and made these cells more sensitive to interferon, which could improve treatment options. Who this helps: This research benefits patients with MDS, particularly those with SRSF2 mutations.

Plain English
This study looked at the thinking and learning abilities of children being treated for acute lymphoblastic leukemia (ALL) during the first month of chemotherapy. Out of 406 children, 330 participated, and over 63% showed normal cognitive function for their age. However, older children had slower reaction times and attention spans, and boys tended to be quicker at tasks than girls, while girls were better at visual learning. Who this helps: This research benefits children with ALL and their families by identifying those who may need closer monitoring for cognitive issues.

Plain English
This study focuses on a new technique called direct-write vapor deposition, which allows for the precise layering of materials to create 3D patterns without using masks. Researchers developed a microevaporator that releases materials through tiny nozzles, allowing them to accurately deposit substances in specific patterns on various surfaces. They found that by adjusting the distance between the nozzles and the surfaces, they could control the width of the deposited lines, which is crucial for designing nanoscale devices. Who this helps: This benefits engineers and scientists working on advanced materials for electronics and other technologies.

Plain English
This study looked at how a bone marrow biopsy performed on Day 14 of treatment can predict overall survival and relapse-free survival in patients with acute myeloid leukemia (AML). The researchers found that the results from this early biopsy did not significantly correlate with patient outcomes. This matters because it suggests that doctors may not need to rely on Day 14 biopsy results to make predictions about a patient's future health. Who this helps: This helps doctors who treat patients with acute myeloid leukemia.

Plain English
This study looked at a type of blood cancer called acute myeloid leukaemia and how certain mutations (specifically RAS mutations) cause resistance to a treatment called venetoclax. The researchers found that RAS mutations only occur in the later stages of the disease, specifically in leukaemia stem cells, which can lead to a more severe form of the disease that does not respond well to treatment. They discovered that about 70% of patients with RAS mutations had poor responses to venetoclax, indicating that these mutations significantly impact treatment outcomes. Who this helps: This research benefits patients with acute myeloid leukaemia, particularly those with RAS mutations.

Plain English
This study focused on creating and testing a bilingual chatbot named "Ana" to provide accurate COVID-19 information to historically excluded communities, especially Black and Latin American groups. Over 626 community members used the chatbot between August 2021 and March 2022, with 63.87% of English users and 22.14% of Spanish users returning for additional information. The positive user feedback shows that Ana effectively addressed important public health concerns, highlighting the importance of accessible COVID-19 resources during the pandemic. Who this helps: This aids patients from marginalized communities seeking reliable COVID-19 information and support.

Plain English
This study looked at mutations in certain genes that affect how RNA is spliced in patients with a condition called myelodysplastic syndrome (MDS). Researchers discovered that a specific form of a gene called GNAS (GNAS-L) is involved in driving MDS in patients with mutations in splicing factors. They found that GNAS-L leads to increased activity in a signaling pathway important for cell growth, making these cancer cells responsive to a type of targeted therapy called MEK inhibitors. Who this helps: This research benefits patients with myelodysplastic syndrome and similar conditions caused by splicing factor mutations.

Plain English
This research studied infants with a specific type of leukemia called KMT2A-germline acute lymphoblastic leukemia (ALL) to understand their survival outcomes and factors affecting them. Among 167 infants, those younger than 6 months had a 91% chance of staying cancer-free for six years, compared to 71.7% for older infants. The study highlighted that low levels of cancer remnants in the bone marrow (measured at the end of initial treatment) are linked to better survival rates, with a 6-year disease-free survival rate of 87.9% for those with no detectable cancer remnants, compared to only 61.4% for those with high levels. Who this helps: This information benefits doctors and researchers working on leukemia treatments for infants.

Plain English
This study looked at how easy it is for people living with HIV in Europe to access medically assisted reproduction (MAR) services. Researchers found that while MAR is available in 12 out of 14 countries, many face challenges such as high costs and restrictions that affect single women and same-sex couples. Understanding these barriers is important because it can help improve access to fertility services for those living with HIV. Who this helps: This benefits patients seeking fertility treatments, particularly those living with HIV, single women, and same-sex couples.

Plain English
This study looked at how combining curcumin with SN-38, a strong cancer treatment, improves the delivery of the drug when loaded into tiny particles called nanoparticles. Researchers found that adding curcumin increased the amount of SN-38 that could be effectively encapsulated by up to 10 times and improved the uniformity of the nanoparticles. This is important because a more effective delivery system could mean better treatment options for patients with certain types of cancer. Who this helps: Patients with cancer, especially those who might benefit from improved drug delivery.

Plain English
This study looked at how to improve bioprocess development—how we grow cells for products like vaccines—by using a combination of experimental design and artificial intelligence. The researchers found that using their new method, which combines traditional experimental design with artificial neural networks (ANNs), leads to more accurate bioprocess outcomes compared to older methods. Specifically, they highlighted that the ANN approach is a more powerful tool for optimizing cell growth than the simpler "change one thing at a time" method traditionally used. Who this helps: This benefits scientists and engineers working in biotechnology and pharmaceuticals.

Plain English
This research focused on improving the production of therapeutic cells that can treat back pain caused by disc degeneration. The study found that using stirred tank bioreactors allowed for a scalable method to grow these cells effectively, achieving similar quality to traditional methods, while increasing production size by 200 times. This advancement in cell production technology is crucial for making such therapies more widely available to patients. Who this helps: Patients with lumbar disc degeneration.

Plain English
The research paper studies the treatment and management of pediatric acute lymphoblastic leukemia (ALL), the most common cancer in children. It highlights how new technologies and tailored therapies have improved survival rates, but points out that children with high-risk ALL, including specific types like T-ALL and infant ALL, still need better treatment options after relapse. The guidelines provide detailed recommendations on diagnosis, treatment, and support for these patients to help improve their outcomes. Who this helps: This benefits children with acute lymphoblastic leukemia and their doctors.

Plain English
This research looks at how to make cell therapies more effective for treating joint and disc diseases, which often fail in human trials. The study found that tough conditions in places like the knee and spine, such as low oxygen, high acidity, and inflammation, make it hard for these therapies to work well. By understanding these challenges and finding ways to improve cell function and survival in these environments, the hope is to develop more reliable treatments. Who this helps: This helps patients suffering from musculoskeletal diseases and their healthcare providers.

Plain English
This study looked at how safe new drugs called squalene epoxidase (SQLE) inhibitors are for treating small cell lung cancer (SCLC), a severe type of lung cancer. Researchers found that when tested in dogs and monkeys, these drugs caused harmful side effects, especially gastrointestinal issues, even at levels lower than needed for them to be effective against tumors. This matters because it suggests that these drugs might not be practical options for treating SCLC due to their harmful effects. Who this helps: This helps doctors and researchers who are looking for safe treatment options for small cell lung cancer patients.

Plain English
The study focused on improving the use of a drug called asparaginase in treating children with acute lymphoblastic leukaemia (ALL), as many patients stop or don’t receive it fully due to reactions and side effects. Experts found that monitoring drug levels closely and using medications to prevent reactions can help more children complete their treatment. They stressed the need for more research on whether patients can safely continue asparaginase after major side effects like pancreatitis or brain complications occur. Who this helps: This helps young cancer patients and their doctors.

Plain English
This research studied a new drug called AG-348, which aims to help people with a condition known as pyruvate kinase deficiency, a type of anemia caused by enzyme problems. In tests with healthy volunteers, the researchers found that AG-348 was generally safe, with some common side effects including headaches and nausea in about 16% and 14% of participants, respectively. The drug showed promising effects on the body's sugar processing system, indicating it could be valuable for treating anemia in future studies. Who this helps: This helps patients with pyruvate kinase deficiency and other forms of anemia.

Plain English
This study focused on creating tiny drug-carrying particles (called nanoparticles) that deliver a cancer drug called SN-38. The researchers found that increasing the speed of the liquid flow during manufacturing improved how well the drug was loaded into the nanoparticles and affected how quickly the drug was released. Specifically, at the fastest flow rate, they achieved better drug release profiles compared to traditional methods, leading to smaller particles that may work better against cancer cells. Who this helps: This benefits cancer patients by potentially improving the effectiveness of their treatments.

Plain English
This study looked at the impact of atomoxetine (a medication) and parent training on children with autism spectrum disorder who also showed signs of ADHD. Researchers found that, after 10 weeks, parents reported less stress regardless of the treatment they received, but the level of improvement was similar across all groups. Notably, parents whose children responded well to treatment saw a greater decrease in stress. Who this helps: This research helps parents of children with autism and ADHD.

Plain English
This study looked at how atomoxetine, a medication, and a parent training program could improve sleep for children who have both autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). After 10 weeks, the researchers found that none of the treatments significantly improved sleep quality when compared to a placebo, meaning that atomoxetine didn't worsen sleep issues. This is important because it shows that doctors can consider using atomoxetine for children with these conditions without worsening their sleep. Who this helps: This helps doctors and parents of children with ASD and ADHD.

Plain English
This study looked at how well nurses understand and feel about using urinary catheters, which are often linked to infections in critically ill patients. After training, the nurses’ knowledge improved significantly, with average scores rising from 76% to nearly 87%. However, their attitudes towards preventing infections did not change much. This matters because better training leads to safer care and fewer infections. Who this helps: This helps patients in hospitals by reducing their risk of urinary infections.

Plain English
This study looked at how well a non-invasive test for measuring liver stiffness, called acoustic radiation force impulse (ARFI), works for children who have had a Fontan heart surgery. The researchers found that ARFI measurements did not relate strongly to the patients' heart and lung function during exercise tests, with a correlation score of just 0.20, which suggests little connection. This matters because understanding the relationship between liver health and overall cardiovascular fitness is crucial for improving care in these patients and may help identify better ways to monitor their health over time. Who this helps: This helps patients with single ventricle heart disease and their doctors.

Plain English
This research focused on a new drug called AG-120 (ivosidenib) designed to target a specific mutation in the IDH1 gene that is common in certain cancers. The findings showed that the drug effectively reduced a harmful substance called 2-HG in cancer cells and helped some cancer cells develop normally again in laboratory tests. In early clinical trials, AG-120 appeared to be safe and showed positive effects for patients with IDH1 mutant cancers. Who this helps: Patients with cancers that have IDH1 mutations.

Plain English
This study explored a new way to treat damaged discs in the spine by using human cells that are taken directly from storage without needing to be prepared in advance. Researchers tested this method on dogs with spine issues and found that the treated discs maintained their height better and showed healthier tissue characteristics compared to untreated discs after 12 weeks. This is important because it suggests that these ready-to-use cells could effectively help prevent further degeneration of spinal discs in people. Who this helps: This benefits patients with degenerative disc disease.

Plain English
This study looked at the quality of life for children with acute lymphoblastic leukemia during and after treatment, comparing results from two different clinical trial protocols. Researchers found that quality of life improved steadily throughout treatment in both groups, but high-risk patients had lower scores than standard-risk patients. Specifically, patients on the newer DFCI 00-01 protocol had slightly fewer quality-adjusted life years than the general population, highlighting areas for further support. Who this helps: This benefits children with leukemia and their families by providing insights on treatment impacts and areas for better care.

Plain English
The study looked at new treatments using cell therapies to fix damaged intervertebral discs, which can cause chronic back pain. Researchers found that these therapies are promising and could be low-cost and effective but have not yet been used widely in clinics. The paper identifies key challenges, such as how to improve cell delivery and reduce risks, to help bring these treatments to patients more quickly. Who this helps: This benefits patients suffering from chronic low back pain.

Plain English
The study focused on a new drug called AG-221, designed to treat a specific type of blood cancer called acute myeloid leukemia (AML) that has particular gene mutations. Researchers found that AG-221 reduces harmful substances in cancer cells and helps them mature into normal cells, leading to improved survival rates in laboratory mice with this aggressive form of leukemia. This is significant because about 20% of AML patients have these mutations, and AG-221 shows promise as a new treatment option. Who this helps: Patients with acute myeloid leukemia who have specific gene mutations.

Plain English
This study looked at how blood cancers, specifically myeloid malignancies, progress through different stages, from early signs (like pre-leukemia) to more severe forms like acute myeloid leukemia (AML). Researchers created stem cell lines that represent these stages and found that each stage has distinct characteristics that indicate how the disease worsens. They also discovered that they could simulate changes in the disease’s progression using genetic techniques, which can help test new drugs tailored to specific disease stages. Who this helps: This research benefits patients with blood cancers and their healthcare providers by improving understanding of the disease and leading to better treatment options.

Plain English
This study looked at AG-348, a new drug being tested to treat pyruvate kinase deficiency, a rare genetic condition that causes anemia. Researchers found that AG-348 increases the activity of the pyruvate kinase enzyme in both normal and flawed versions found in patients, suggesting it could help correct the underlying issue in their red blood cells. This matters because, if successful, AG-348 could be the first targeted treatment for a condition that currently has no specific therapies. Who this helps: This helps patients with pyruvate kinase deficiency.

Plain English
This study looked at how infants with relapsed acute lymphoblastic leukemia (a type of blood cancer) responded to a specific treatment plan called the interfant-99 protocol. Researchers found that about 58% of the infants treated had their cancer go into remission, which is a significant improvement. These results are important because they show that this treatment can effectively help very young children with this serious illness. Who this helps: This helps infants with relapsed acute lymphoblastic leukemia and their families.

Plain English
This study explored how two drugs, valproic acid and scriptaid, affect stem cells from umbilical cord blood. Researchers found that each drug created distinct changes in the genes and functions of these cells, which are important for blood development and transplantation. For instance, valproic acid activated genes that help the body respond to stress, supporting the growth and maintenance of blood stem cells, which plays a crucial role in improving outcomes for patients in need of blood cell transplants. Who this helps: Patients requiring blood stem cell transplants.

Plain English
This study looked at how satisfied caregivers were with a clinical trial that tested the medication atomoxetine and a parent training program for children with autism who also have ADHD and behavior issues. Out of 128 participating children, 93% of caregivers completed a satisfaction questionnaire, with 87% saying they would join the study again and 92% willing to recommend it to others. These findings highlight that caregivers found the research experience generally positive, which is important for designing future studies that are family-friendly. Who this helps: This helps caregivers of children with autism and ADHD, as well as researchers planning future studies.

Plain English
This study looked at how orthopedic surgeons use social media platforms like blogs, Facebook, and Twitter to improve communication with patients and colleagues. It found that while social media can help doctors connect more effectively, it also poses risks and limitations in patient care. Understanding both the advantages and challenges of social media is important to make sure patients receive the best care possible. Who this helps: This helps orthopedic surgeons and their patients.

Plain English
This study looked at a rare condition called D-2-hydroxyglutaric aciduria type II, which is caused by a specific mutation in the IDH2 gene and leads to symptoms like heart disease and developmental issues. Researchers tested a drug called AGI-026 on mice with this mutation and found that it lowered the harmful chemical D-2-hydroxyglutarate, improved heart function, and helped the mice live longer. This is important because it shows that targeting the faulty IDH2 enzyme with a specific drug may help treat patients suffering from this disorder. Who this helps: This helps patients with D-2-hydroxyglutaric aciduria type II and their families.

Plain English
Researchers created a mouse model to study PMM2-CDG, a genetic disorder with no current treatments. They discovered that many of the mice died before birth, and those that survived grew significantly slower than normal mice. This growth issue was linked to problems with how proteins were modified in their bodies, similar to what happens in people with PMM2-CDG. Importantly, they found that fixing the genetic defect in cells improved these issues, suggesting a new way to develop treatments. Who this helps: This helps patients with PMM2-CDG and their families.

Plain English
The 33rd Annual Symposium of the Society of Toxicologic Pathology focused on how the study of toxic substances can improve human health. Researchers discussed how toxicologic pathologists assess the effects of drugs, chemicals, and environmental factors on health, aiming to better understand the risks associated with these exposures. This is important because it helps in identifying hazards and communicating risks to protect both people and animals from potentially harmful substances. Who this helps: Patients, doctors, and public health officials benefit from this research.

Plain English
This study focused on adapting and testing a questionnaire called QoLISSY, which measures how children and teens with short stature feel about their quality of life. Researchers worked with 28 families to ensure the American version was understandable and relevant, then tested it with 51 families and found that it effectively captured differences in quality of life based on height. The findings indicated that taller children reported a better quality of life, and the questionnaire showed strong reliability, making it suitable for research and clinical use in the United States. Who this helps: This benefits children and teens with short stature and their families.

Plain English
This research studied how the anticancer drug Doxil® releases its active ingredient, doxorubicin, more effectively at tumor sites due to the presence of ammonia, which is produced by tumor cells. The scientists found that when ammonia is present, Doxil kills tumor cells as effectively as free doxorubicin, while neither Doxil without ammonia nor ammonia alone can kill tumor cells. This matters because understanding how Doxil releases its drug in the tumor environment can help improve cancer treatments by targeting tumors more effectively. Who this helps: This helps cancer patients by potentially improving the effectiveness of their treatments.

Plain English
This study looks at a 5-year-old boy with leukemia who developed a serious brain infection called a cerebral abscess while undergoing chemotherapy. The doctors found a type of bacteria called Bacillus cereus in his blood, which is known to cause severe infections in patients with weakened immune systems. After treatment with antibiotics, his brain infection cleared up, highlighting the importance of quick diagnosis and treatment for patients at risk of such infections. Who this helps: This helps doctors and patients undergoing chemotherapy for leukemia.

Plain English
This study looked at how to design clinical trials for new cancer treatments when there are no existing standard options, specifically focusing on a trial called AZA-001 that tested a drug called azacitidine against three commonly used treatments for high-risk myelodysplastic syndromes. The researchers found that allowing doctors to choose the best treatment for each patient before randomizing them to either azacitidine or one of the conventional care regimens made the trial more effective, as it included patients who might otherwise not qualify for a standard comparison. This approach is important because it could help create better trials for other cancers without established treatments. Who this helps: This helps patients with cancers that currently have no standard treatment options.

Plain English
This study looked at how children with autism develop their language skills compared to children without autism. Researchers found that some language differences between the two groups stayed the same as children grew older, but kids with autism improved in their ability to stay on the topic during conversations. This is important because it shows that while certain language challenges are consistent, there are also areas of improvement that can be tracked over time. Who this helps: This helps educators and clinicians working with children with autism.

Plain English
This study looks at how important it is for patients and healthcare providers to work together in making decisions about treatment, especially with the rising use of alternative medicines. The researchers found that when patients and providers communicate openly, it leads to better health outcomes. This is important because it shows that involving patients in their own care is crucial for improving overall health. Who this helps: Patients looking for effective and personalized healthcare options.